Candriam S.C.A. Arcutis Biotherapeutics, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 1,426,496 shares of ARQT stock, worth $19.4 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,426,496
Previous 1,307,481
9.1%
Holding current value
$19.4 Million
Previous $12.2 Million
9.1%
% of portfolio
0.08%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$158 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$149 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$145 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$119 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$117 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $817M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...